# Thymulin Dosage in Research: Routes, Doses, and Pharmacokinetics

> Thymulin dosage in published research: rodent study doses, routes, half-life (~10 min), nanoparticle and gene therapy approaches. No human clinical dosing data exists. Species-specific research context only.

## Thymulin Dosage in Research: Routes, Doses, and Pharmacokinetics

Thymulin has been studied across multiple rodent models using intraperitoneal, intracerebroventricular, and intratracheal routes. No human clinical dosing data exists — no Phase 1, 2, or 3 trials of exogenous Thymulin administration in humans have been published. The figures below are research context only: what was administered to which species at which dose in which study.

## Thymulin Dosage in Published Research

Representative examples from the peer-reviewed record:

| Study | Species | Dose | Route | Endpoint |
|---|---|---|---|---|
| Lunin et al., 2008 [12] | Mouse (NMRI) | 15 µg/100 g | i.p. | Pro-inflammatory cytokine suppression |
| Novoselova et al., 2014 [13] | Mouse (BALB/c) | 1.5 mg/kg | i.p. | NF-kappaB inhibition |
| Novoselova et al., 2018 [19] | Mouse (BALB/c) | 1.5 mg/kg | i.p. | Chronic septic inflammation |
| Lunin et al., 2015 [18] | Mouse (C57BL/6) | 0.15 mg/kg every other day | i.p. | EAE disease severity |
| Safieh-Garabedian et al., 2002 [15] | Rat (Sprague-Dawley) | 25–50 µg | i.p. | Analgesic, anti-inflammatory (PAT) |
| Nasseri et al., 2019 [14] | Rat (CFA model) | Research doses | i.p. | Thermal hyperalgesia |
| Haddad and Hanbali, 2013 [17] | Rat | 1–25 µg (dose-dependent) | i.c.v. | NF-kappaB inhibition in hippocampus |
| Hadley et al., 1997 [23] | Rat pituitary (in vitro) | 0.5–50 pM (optimal 10 pM) | In vitro | ACTH release |
| Oliver and Marsh, 2003 [11] | Avian (chicken) | Various; 50 ng/100g suppressive | Injection | NK cell cytotoxicity |

## Pharmacokinetic Profile

Thymulin's plasma half-life is approximately 10 minutes in rodent models.[19] The zinc-free apothymulin is biologically inactive. Alpha-2-macroglobulin can compete with thymulin for zinc binding even when total plasma zinc appears normal.[10]

Circadian variation: thymulin follows a circadian rhythm with peak serum levels at approximately 1:00 a.m. in rodent studies.[23, 24] No validated human pharmacokinetic data has been published.

## Routes Studied

- **Intraperitoneal** — most common in rodent studies[12, 13, 14, 15, 18, 19]
- **Intracerebroventricular** — CNS neuroprotection studies[17]
- **Intratracheal** — lung/asthma gene therapy nanoparticle delivery[26]
- **In vitro** — pituitary ACTH stimulation, PBMC, macrophage experiments[4, 23]
- **Subcutaneous** — referenced in pharmacokinetic overviews
- **Nanoparticle-bound** — PBCA nanoparticles as half-life extension strategy[19, 27]
- **Gene therapy vector** — adenoviral and CK30PEG nanoparticle delivery of synthetic metFTS gene[20, 21, 26]

No oral thymulin administration studies have been identified in the reviewed literature.

## Delivery System Research: Addressing the 10-Minute Half-Life

**PBCA nanoparticles.** Thymulin bound to polybutylcyanoacrylate nanoparticles demonstrated superior efficacy versus free thymulin in chronic septic inflammation mice (Novoselova et al., 2018)[19] and relapsing-remitting EAE models (Novoselova et al., 2019).[27]

**Gene therapy.** Adenoviral vector delivery of synthetic metFTS achieved sustained biologically active thymulin expression for 112+ days in rodent models.[21] DNA nanoparticle (CK30PEG) delivery resolved experimental allergic asthma pathology within 20 days following a single intratracheal dose.[26]

Both approaches remain pre-clinical. No human trials have been conducted.

## Safety and Adverse Effects in the Research Record

Pre-clinical literature reports minimal acute toxicity at studied doses in rodent models. The PAT analog study (Safieh-Garabedian et al., 2002) reported no significant adverse effects at 25–50 µg i.p. in rats.[15]

Two theoretical concerns noted in the research literature:

1. **Immunostimulatory compounds carry a theoretical autoimmune risk.** The EAE studies show anti-inflammatory effects rather than worsening.[18, 27]
2. **Biphasic dose-response on pain signaling.** At nanogram-range doses, thymulin may be pro-nociceptive; at microgram doses it is analgesic.[25]

No human safety data exists.

## References

[10] Mocchegiani E, et al. Role of zinc and alpha-2 macroglobulin on thymic endocrine activity in cervical carcinoma. Br J Cancer. 1999;79(3-4):358-365. https://pmc.ncbi.nlm.nih.gov/articles/PMC2362212/
[11] Oliver MA, Marsh JA. In vivo thymulin treatments enhance avian lung NK cell cytotoxicity. Int Immunopharmacol. 2003;3(2):241-252. https://pubmed.ncbi.nlm.nih.gov/12538040/
[12] Lunin SM, et al. Thymulin prevents overproduction of pro-inflammatory cytokines. Immunol Invest. 2008;37(8):858-873. https://pubmed.ncbi.nlm.nih.gov/18991101/
[13] Novoselova EG, et al. Anti-Inflammatory Effects of IKK Inhibitor XII, Thymulin. Mediators Inflamm. 2014;2014:724838. https://pmc.ncbi.nlm.nih.gov/articles/PMC4089567/
[14] Nasseri B, et al. Thymulin treatment attenuates inflammatory pain. Int Immunopharmacol. 2019;70:89-97. https://pubmed.ncbi.nlm.nih.gov/30851702/
[15] Safieh-Garabedian B, et al. Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide. Br J Pharmacol. 2002;136(3):421-428. https://pmc.ncbi.nlm.nih.gov/articles/PMC1573422/
[17] Haddad JJ, Hanbali LH. Anti-Inflammatory Activity of Thymulin Peptide is NF-kappaB-Dependent. Am J Med Biol Res. 2013;1(2):35-44. https://pubs.sciepub.com/ajmbr/1/2/2/
[18] Lunin SM, et al. Modulation of inflammatory response by thymulin. Int Immunopharmacol. 2015;25(2):368-374. https://pubmed.ncbi.nlm.nih.gov/25662754/
[19] Novoselova EG, et al. Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation. PLoS ONE. 2018;13(5):e0197601. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197601
[20] Reggiani PC, et al. Neonatal Thymulin Gene Therapy Prevents Ovarian Dysgenesis. Endocrinology. 2012;153(8):3922-3931. https://pmc.ncbi.nlm.nih.gov/articles/PMC3404341/
[21] Reggiani PC, et al. Thymulin-Based Gene Therapy and Pituitary Function in Animal Models of Aging. Neuroimmunomodulation. 2011;18(5):279-285. https://pmc.ncbi.nlm.nih.gov/articles/PMC3221262/
[23] Hadley AJ, et al. Thymulin stimulates corticotrophin release in the rat anterior pituitary gland. Neuroimmunomodulation. 1997;4(2):62-69. https://pubmed.ncbi.nlm.nih.gov/9483196/
[24] Reggiani PC, et al. The Thymus-Neuroendocrine Axis. Ann N Y Acad Sci. 2009;1153:98-106. https://pmc.ncbi.nlm.nih.gov/articles/PMC2688715/
[25] Dardenne M, Saade N, Safieh-Garabedian B. Role of thymulin or its analogue as a new analgesic molecule. Ann N Y Acad Sci. 2006;1088:153-163. https://pubmed.ncbi.nlm.nih.gov/17192563/
[26] Nanoparticle-based thymulin gene therapy reverses key pathology of experimental allergic asthma. Sci Adv. 2020;6(25):eaay7973. https://pmc.ncbi.nlm.nih.gov/articles/PMC7286682/
[27] Novoselova EG, et al. Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against EAE in Mice. Int J Mol Sci. 2019;20(21):5374. https://pmc.ncbi.nlm.nih.gov/articles/PMC6862195/

---

The peer-reviewed thymulin record, cited at the source — not a clinic, not a vendor.